No Prescription

Alpha Index O

No Prescription » Products » Alpha Index O

List of Drugs:

A  B  C  D  E  F  G  H  I  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Z  #

Products O:

OCUVIR Zovirax

ODIVIR Sustiva

Oestrogel Generic Estradiol

OGLO Actos

OKABAX MD Generic Vioxx

OKACET Zyrtec

OKAMET Fortamet

OLAMIN Loprox

OLIZA Zyprexa

OLMECIP Benicar

Olmecip H Benicar H

OLMEZEST BENICAR

Olsar A Azor

Ol Vamlo Generic Olmesartan

OMECIP Losec

Omeprazole Generic Prilosec

Omnacortil Prednisone

ONE ALPHA AlfaD

Onglyza Generic Saxagliptin

OPTIPRES S Betoptic

ORIPHEX Biocef

Orlistat Generic orlistat

Ospamox Amoxil

OSRAL Evista

OSTEOFOS Fosamax

Ostospray Miacalcin

OTRIVIN Natru Vent

Ovestin Generic Oestriol

Ovestin Vaginal Cream Generic Oestriol

OVRAL L Ovranette

Ovral (Norgestrel + Ethinyl Estradiol)

OXCARB Trileptal

OXYSPAS Ditropan

Previous  Next

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.